Jonathan Behr - Profile and Investment Details

Investor Profile

Jonathan Behr is a Venture Capital, Private Equity Firm, Investor based in Cambridge, Massachusetts, United States with a diverse investment portfolio that includes companies such as Gen2 Neuroscience, Solace Pharmaceuticals (UK) Ltd., Nordic, JDRF T1D Fund, Violet Therapeutics, Alector, Mitoconix BioAstronauTx, Diasome Pharmaceuticals, Inc., BrainWaveBank, Nitrome Biosciences, Cerevance, QurAlis, Amathus Therapeutics, Transine Therapeutics, Ribometrix, Semma Therapeutics, Provention Bio, a Sanofi Company, Autifony Therapeutics, Enthera Pharmaceuticals, Exosome Diagnostics, Tiaki Therapeutics, ImmusanT, Parkinson's UK, Entrega Inc., Inversago Pharma, Evelo Biosciences, Caraway Therapeutics, Nitrase Therapeutics, Therini Bio, AnTolRx, SQZ Biotechnologies, . Over time, Jonathan Behr has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Jonathan Behr is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Women Founded, Life Science, Biotechnology, Market Research, Electronic Health Records (EHR), Health and Hospital Services, Neuroscience, Clinical Trials, Health Diagnostics, Digital Health, Medical, Therapeutics, Pharmaceuticals may find it worthwhile to explore potential connections with Jonathan Behr, as their portfolio suggests a familiarity and interest in this area.

Understanding Jonathan Behr’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.